The Goldman Sachs Group Issues Pessimistic Forecast for Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Price

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price target lowered by research analysts at The Goldman Sachs Group from $536.00 to $320.00 in a research report issued on Friday, Benzinga reports. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. The Goldman Sachs Group‘s target price would indicate a potential upside of 88.16% from the company’s previous close.

Other research analysts have also recently issued reports about the company. Truist Financial dropped their target price on Alnylam Pharmaceuticals from $410.00 to $315.00 and set a “buy” rating on the stock in a research report on Tuesday, August 4th. UBS Group restated a “buy” rating and set a $329.00 target price on shares of Alnylam Pharmaceuticals in a research note on Friday. Barclays decreased their price target on Alnylam Pharmaceuticals from $527.00 to $450.00 and set an “overweight” rating on the stock in a report on Monday, August 3rd. Citigroup lowered their target price on shares of Alnylam Pharmaceuticals from $340.00 to $320.00 and set a “buy” rating on the stock in a report on Wednesday, October 14th. Finally, HC Wainwright restated a “buy” rating on shares of Alnylam Pharmaceuticals in a research report on Wednesday. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat.com, Alnylam Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $328.23.

Alnylam Pharmaceuticals Price Performance

Shares of ALNY traded down $3.93 during midday trading on Friday, hitting $170.07. 3,012,678 shares of the company traded hands, compared to its average volume of 1,499,062. The stock has a 50-day moving average of $237.78 and a 200-day moving average of $287.22. The company has a debt-to-equity ratio of 0.75, a current ratio of 3.05 and a quick ratio of 2.99. Alnylam Pharmaceuticals has a one year low of $167.16 and a one year high of $479.79. The firm has a market cap of $22.76 billion, a P/E ratio of 31.60 and a beta of 0.28.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported $16.26 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.66 by $14.60. The company had revenue of $1.46 billion during the quarter, compared to analysts’ expectations of $1.43 billion. Alnylam Pharmaceuticals had a net margin of 15.26% and a return on equity of 84.93%. The firm’s revenue was up 16.7% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.90 EPS. As a group, sell-side analysts predict that Alnylam Pharmaceuticals will post 6.43 EPS for the current fiscal year.

Insider Buying and Selling

In other news, EVP Bryan Supran sold 1,758 shares of the stock in a transaction dated Friday, October 2nd. The stock was sold at an average price of $226.88, for a total value of $398,855.04. Following the transaction, the executive vice president directly owned 12,807 shares of the company’s stock, valued at approximately $2,905,652.16. This represents a 12.07% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Corporate insiders own 0.86% of the company’s stock.

Institutional Trading of Alnylam Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in ALNY. Provenance Wealth Advisors LLC purchased a new stake in shares of Alnylam Pharmaceuticals in the third quarter worth about $527,000. GraniteShares Advisors LLC lifted its stake in shares of Alnylam Pharmaceuticals by 12.7% in the 3rd quarter. GraniteShares Advisors LLC now owns 1,825 shares of the biopharmaceutical company’s stock valued at $450,000 after purchasing an additional 205 shares during the period. Traynor Capital Management Inc. boosted its holdings in Alnylam Pharmaceuticals by 22.6% during the third quarter. Traynor Capital Management Inc. now owns 12,818 shares of the biopharmaceutical company’s stock worth $3,163,000 after buying an additional 2,360 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. purchased a new position in Alnylam Pharmaceuticals in the third quarter valued at $18,226,000. Finally, Profund Advisors LLC boosted its stake in shares of Alnylam Pharmaceuticals by 22.5% during the 3rd quarter. Profund Advisors LLC now owns 16,919 shares of the biopharmaceutical company’s stock worth $4,175,000 after acquiring an additional 3,105 shares in the last quarter. Institutional investors and hedge funds own 92.97% of the company’s stock.

Key Headlines Impacting Alnylam Pharmaceuticals

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Q3 results exceeded expectations. Alnylam reported $16.26 in adjusted earnings per share versus the $1.66 consensus estimate, while revenue rose 16.7% year over year to $1.46 billion, ahead of estimates. The company maintained its fiscal 2026 net product-sales outlook. Alnylam Q3 earnings and revenue results
• Positive Sentiment: Long-term pipeline prospects remain supportive. Alnylam expects $4.2 billion-$4.5 billion in 2026 TTR sales and expanded the TRITON-CM nucresiran heart-disease study to approximately 2,250 patients while maintaining an expected launch timeline around 2030. Alnylam TTR sales and TRITON-CM update
• Neutral Sentiment: Analysts remain divided. Wells Fargo lowered its target to $220 and kept an “equal weight” rating; RBC cut its target to $280 but retained “outperform”; and Needham reduced its target to $243 while maintaining “buy.” These targets still imply substantial potential upside from recent levels.
• Negative Sentiment: Demand growth is the immediate concern. Slower U.S. Amvuttra patient starts and moderating Amvuttra and Onpattro sales growth raised questions about the pace of commercial expansion despite the quarterly beat. Alnylam demand growth concerns
• Negative Sentiment: Broker sentiment weakened. Bernstein downgraded Alnylam to “market perform” with a $199 target, while Stifel cut its rating to “hold” and set a $225 target. The reductions reflect greater caution around near-term growth and valuation.
• Negative Sentiment: Additional risk overhangs remain. An investor law firm announced an investigation related to a prior company disclosure, potentially adding to market uncertainty, although no wrongdoing has been established. Alnylam investor investigation

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing medicines based on RNA interference (RNAi). The company’s therapies are designed to silence specific genes involved in disease, with the goal of addressing the underlying causes of genetic and other serious conditions.

Alnylam’s marketed products include ONPATTRO (patisiran) and AMVUTTRA (vutrisiran) for hereditary transthyretin-mediated amyloidosis, GIVLAARI (givosiran) for acute hepatic porphyria, and OXLUMO (lumasiran) for primary hyperoxaluria type 1.